These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18649014)

  • 1. The politics and bio-ethics of regulatory trust: case-studies of pharmaceuticals.
    Abraham J
    Med Health Care Philos; 2008 Dec; 11(4):415-26. PubMed ID: 18649014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institutional mistrust in the organization of pharmaceutical clinical trials.
    Fisher JA
    Med Health Care Philos; 2008 Dec; 11(4):403-13. PubMed ID: 18633728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?
    Abraham J; Ballinger R
    Soc Sci Med; 2012 Oct; 75(8):1433-40. PubMed ID: 22784375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
    Davis C; Abraham J
    Sociol Health Illn; 2011 Jul; 33(5):731-47. PubMed ID: 21314687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug evaluation and the permissive principle: continuities and contradictions between standards and practices in antidepressant regulation.
    Abraham J; Davis C
    Soc Stud Sci; 2009 Aug; 39(4):569-98. PubMed ID: 19848109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The science and politics of medicines control.
    Abraham J
    Drug Saf; 2003; 26(3):135-43. PubMed ID: 12580644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex, gender, and pharmaceutical politics: From drug development to marketing.
    Fisher JA; Ronald LM
    Gend Med; 2010 Aug; 7(4):357-70. PubMed ID: 20869636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
    Davis C; Abraham J
    Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID vaccine confidence requires radical transparency.
    Nature; 2020 Oct; 586(7827):8. PubMed ID: 32994572
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ethical problems in planning therapy studies].
    Baltzer J
    Kinderkrankenschwester; 2013 Jun; 32(6):216-9. PubMed ID: 23822052
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulating the market in human research participants.
    Lemmens T; Miller PB
    PLoS Med; 2006 Aug; 3(8):e330. PubMed ID: 16866575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific misconduct, the pharmaceutical industry, and the tragedy of institutions.
    Cohen-Kohler JC; Esmail LC
    Med Law; 2007 Sep; 26(3):431-46. PubMed ID: 17970244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France.
    Wiktorowicz ME
    J Health Polit Policy Law; 2003 Aug; 28(4):615-58. PubMed ID: 12956518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Industry-funded breast cancer trials show more positive results.
    Gardner A
    Int J Health Serv; 2007; 37(3):591-3. PubMed ID: 17844937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US Nationwide Disclosure of Industry Payments and Public Trust in Physicians.
    Kanter GP; Carpenter D; Lehmann LS; Mello MM
    JAMA Netw Open; 2019 Apr; 2(4):e191947. PubMed ID: 30977850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do gifts from the pharmaceutical industry affect trust in physicians?
    Green MJ; Masters R; James B; Simmons B; Lehman E
    Fam Med; 2012 May; 44(5):325-31. PubMed ID: 23027114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critique of emerging European legislation in the pharmaceutical industry: a clinical trials analysis.
    Murray E; McAdam R; Burke MT
    Int J Health Care Qual Assur Inc Leadersh Health Serv; 2004; 17(7):389-93. PubMed ID: 15552394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research in the physician's office: navigating the ethical minefield.
    Snyder L; Mueller PS
    Hastings Cent Rep; 2008; 38(2):23-5. PubMed ID: 18457224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.